To Observe the Psychophysiological Alterations in Traumatic Stress Subjects
Effects of the Guided Disclosure Protocol on Post-Traumatic Growth: A Randomized Control Trial Designed to Observe Psychophysiological Alterations in Traumatic Stress Subjects
調査の概要
詳細な説明
Study design:
The study will be conducted as multicenter randomized controlled trial. On the basis of eligibility criteria subjects providing consent to participate in the study will be randomized into two groups, experimental group including those who receive the intervention and a control group receiving control intervention. The study outcomes will be monitored in subjects of both groups at different intervals i.e. at baseline and at 3-month follow-up (post-interventional).
Participants Subjects for the present study will be recruited from 5 centers (based in Karachi, Pakistan). The targeted population includes subjects from diverse ethnicity and considered eligible for participation in the study if they indicated in a pre-screening form that they had experienced traumatic event. These subjects will be invited to participate in the study through advertisement on notice board of each center. A written informed consent will be obtained from each study subject after providing detailed information regarding objectives of the study and its duration.
Interventions
The experimental intervention (GDP):
It includes three writing sessions of 20 minutes where the participants will be made to recall the facts regarding the traumatic event first and then the emotions triggered related to the revealed facts will be channelized. The information related to the immediate priority changes due to the revival of the traumatic history and its reflection on current feelings will be collected. Moreover, the learned coping mechanisms will also be inquired and how the traumatic event altered their vision and their personalities and how it helps in coping with future difficulties.
The original instructions will be translated into local language and altered according to the specific traumatic experience.
In the following, a fusion of the tasks concerning each of the three writing sessions is shown.
- Participants will be required to describe memories associated with traumatic event in a sequential order, with an objective and detached attitude
They will be asked to describe
- Their opinion regarding the traumatic event and emotions perceived during the experience
- Its impact on their daily lives, and how it has altered their attitudes toward life.
The actual situation will be focused, while reviving the whole traumatic event experience which aids in exploring the following aspects:
- Present thoughts and feelings regarding the traumatic experience, and also clarify the differences between the ones felt at the time of traumatic event in comparison to the current feelings.
- How much they understand and appreciate themselves for successfully dealing with the traumatic event
- To what extent the traumatic event has modified their vision, attitude, knowledge, and skills, and how it can help in their future;
- What will be their future reactions to other similar events. For the writing session it is mandatory to maintain standard experimental environment with maximum silence so that the subject can write peacefully without getting disturbed. Two weeks after the initial assessment, the first writing session will be performed followed by two sessions once every 2 weeks.
The control intervention:
In control intervention the subjects will be required to take three 20-minute writing sessions, in which they will be asked to write about their daily events of the past week, the writing must focus on the facts and highlight an objective and detached attitude. It has shown potential improvements after the guided disclosure protocol (GDP). Works through the placebo effect. Same protocol will be followed for these subjects as the one used for GDP.
A day prior to each writing session, in both conditions either experimental or control the researcher will communicate with each study subject via telephone in order to give them a reminder to perform the writing task and to check their understanding regarding the instructions given in the booklet. Details regarding the inability to contact the subject will also be recorded in the patient form.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Sindh
-
Karachi、Sindh、パキスタン、78500
- Shamoon Noushad
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Must be disease free, there must be no evidence of any metastatic disease
- Property of written and spoken the English language.
- Experienced any traumatic event in the last 12 Months
Exclusion Criteria:
- Subjects who received a structured psychological intervention for at least 6 months during the last 3 years performed by a psychologist or psychiatrist will be excluded.
- Those with a codified psychiatric disorder (according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) who received Psychopharmacological treatment during the last 3 years will also be excluded from the study sample.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:The experimental intervention (GDP): It includes three writing
|
Guided Disclosure Protocol
|
介入なし:The control intervention:
A day prior to each writing session, the researcher will communicate with each study subject via telephone in order to give them a reminder to perform the writing task and to check their understanding regarding the instructions given in the booklet.
Details regarding the inability to contact the subject will also be recorded in the patient form.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Post-Traumatic Growth (PTG)
時間枠:3 Months
|
Change in the Post-traumatic Growth Inventory (PTGI) will be observed among the subjects enrolled in the GDP group as compared to the control group.
|
3 Months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
C- Reactive Protein (CRP)
時間枠:3 Months
|
Change in the CRP level will be observed among the subjects enrolled in the GDP group as compared to the control group.
|
3 Months
|
Brain-derived neurotrophic factor (BDNF)
時間枠:3 Months
|
Change in the BDNF level will be observed among the subjects enrolled in the GDP group as compared to the control group.
|
3 Months
|
Interleukin-6 (IL-6)
時間枠:3 Months
|
Change in the IL-6 level will be observed among the subjects enrolled in the GDP group as compared to the control group.
|
3 Months
|
Glutamate
時間枠:3 Months
|
Change in the Glutamate level will be observed among the subjects enrolled in the GDP group as compared to the control group.
|
3 Months
|
Cortisol
時間枠:3 Months
|
Change in the Cortisol level will be observed among the subjects enrolled in the GDP group as compared to the control group.
|
3 Months
|
Alpha waves
時間枠:3 Months
|
Change in the Brain waves (Alpha waves) will be observed among the subjects enrolled in the GDP group as compared to the control group.
|
3 Months
|
Heart Rate Variability
時間枠:3 Months
|
Change in the Heart Rate Variability will be observed among the subjects enrolled in the GDP group as compared to the control group.
|
3 Months
|
Beta waves
時間枠:3 Months
|
Change in the Brain waves (Beta waves) will be observed among the subjects enrolled in the GDP group as compared to the control group.
|
3 Months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Trauma Symptom Checklist 40 (TSC-40)
時間枠:3 Months
|
Change in the Trauma Symptom Checklist 40 (TSC-40) will be observed among the subjects enrolled in the GDP group as compared to the control group.
|
3 Months
|
Traumatic Stress Scale (Sadaf Stress Scale)
時間枠:3 Months
|
Change in the Traumatic Stress Scale will be observed among the subjects enrolled in the GDP group as compared to the control group.
|
3 Months
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Gandubert C, Scali J, Ancelin ML, Carriere I, Dupuy AM, Bagnolini G, Ritchie K, Sebanne M, Martrille L, Baccino E, Hermes A, Attal J, Chaudieu I. Biological and psychological predictors of posttraumatic stress disorder onset and chronicity. A one-year prospective study. Neurobiol Stress. 2016 Feb 4;3:61-67. doi: 10.1016/j.ynstr.2016.02.002. eCollection 2016 Jun.
- Kalisch R, Muller MB, Tuscher O. A conceptual framework for the neurobiological study of resilience. Behav Brain Sci. 2015;38:e92. doi: 10.1017/S0140525X1400082X. Epub 2014 Aug 27.
- Cai WP, Pan Y, Zhang SM, Wei C, Dong W, Deng GH. Relationship between cognitive emotion regulation, social support, resilience and acute stress responses in Chinese soldiers: Exploring multiple mediation model. Psychiatry Res. 2017 Oct;256:71-78. doi: 10.1016/j.psychres.2017.06.018. Epub 2017 Jun 8.
- Liu AN, Wang LL, Li HP, Gong J, Liu XH. Correlation Between Posttraumatic Growth and Posttraumatic Stress Disorder Symptoms Based on Pearson Correlation Coefficient: A Meta-Analysis. J Nerv Ment Dis. 2017 May;205(5):380-389. doi: 10.1097/NMD.0000000000000605.
- Linz R, Puhlmann LMC, Apostolakou F, Mantzou E, Papassotiriou I, Chrousos GP, Engert V, Singer T. Acute psychosocial stress increases serum BDNF levels: an antagonistic relation to cortisol but no group differences after mental training. Neuropsychopharmacology. 2019 Sep;44(10):1797-1804. doi: 10.1038/s41386-019-0391-y. Epub 2019 Apr 16.
- Alper B, Erdogan B, Erdogan MO, Bozan K, Can M. Associations of Trauma Severity with Mean Platelet Volume and Levels of Systemic Inflammatory Markers (IL1beta, IL6, TNFalpha, and CRP). Mediators Inflamm. 2016;2016:9894716. doi: 10.1155/2016/9894716. Epub 2016 Apr 5.
- Smith HE, Jones CJ, Hankins M, Field A, Theadom A, Bowskill R, Horne R, Frew AJ. The effects of expressive writing on lung function, quality of life, medication use, and symptoms in adults with asthma: a randomized controlled trial. Psychosom Med. 2015 May;77(4):429-37. doi: 10.1097/PSY.0000000000000166.
- Gidron Y, Duncan E, Lazar A, Biderman A, Tandeter H, Shvartzman P. Effects of guided written disclosure of stressful experiences on clinic visits and symptoms in frequent clinic attenders. Fam Pract. 2002 Apr;19(2):161-6. doi: 10.1093/fampra/19.2.161.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- KU-Psychophysiology-5
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
GDPの臨床試験
-
Cancer Institute and Hospital, Chinese Academy...わからない
-
Fudan Universityわからない新生物 | 免疫系疾患 | リンパ腫、B細胞 | リンパ腫、大型B細胞、びまん性 | リンパ増殖性疾患 | リンパ疾患 | 免疫増殖性疾患 | リンパ腫、非ホジキン | ゲムシタビン | シスプラチン | デキサメタゾン | リツキシマブ | シクロホスファミド | チダミデ | 組織学による新生物 | HDAC阻害剤中国
-
Cancer Institute and Hospital, Chinese Academy...完了
-
Shandong Provincial Hospitalわからない肝脾T細胞リンパ腫 | 特に明記されていない末梢性T細胞リンパ腫 | ALK陰性の未分化大細胞型リンパ腫 | 血管免疫芽球性T細胞リンパ腫 | 腸疾患関連T細胞リンパ腫 | T細胞リンパ腫のような皮下脂肪織炎中国
-
Nanjing NingQi Medicine Science and Technology...Jiangsu Cancer Institute & Hospitalわからない
-
Dipenkumar ModiGenmab募集再発がん | 難治性がん | びまん性大細胞リンパ腫アメリカ
-
Seoul National University Hospitalまだ募集していませんびまん性大細胞型B細胞リンパ腫 | 難治性非ホジキンリンパ腫 | 再発非ホジキンリンパ腫大韓民国